Pozen Articles

European Patent Office maintains Pozen's PA/Vimovo patent

12 March 2013

Disappointing FDA views for Bayer's Xarelto and Pozen ulcer drug

22 June 2012

Pozen out-licenses migraine drug candidate to Desitin for EU

9 May 2012

Pozen rockets on positive Ph III trial results with aspirin combo drug

23 March 2012

Pozen sells future royalty rights to Treximet for $75 million

28 November 2011

AstraZeneca and Pozen sue Dr Reddy’s over Vimovo patent

27 April 2011

GlaxoSmithKline and XenoPort respond to FDA on Horizant for RLS; Pozen gets positive advisory recommendation on GI drug

8 November 2010

AstraZeneca gets EU backing for OA/RA drug Vimovo; Merck KGaA appeals EMEA decision on cladribine for MS

11 October 2010

Pozen gets $20 million milestone from AstraZeneca as a result of FDA approval of Vimovo

27 May 2010

AstraZeneca/Pozen’s Vimovo combo drug cleared by US FDA, pushing US firm’s stock up 21%; AZ expands deal with Targacept

4 May 2010

Showing 1-10 of 10 articles

Go to beginningPrevious
  • 1
NextGo to end